Dysregulation of homeobox (HB)-containing genes is becoming increasingly recognized as the underlying basis of many hematologic malignancies. Expression of clustered HB (HOX) genes within the hematopoietic system, and enforced overexpression and knockout studies have provided support for the concept that these homeodomaincontaining transcription factors play a significant role in the developmental biology of hematopoietic cells. Diverged HB (non-HOX) genes have recently been identified as either cofactors and/or accelerators of leukemic disease mediated by HOX genes or as bona fide oncogenes. In this review, we examine the evidence that supports a central role for HB genes in normal and malignant hematopoiesis, paying particular attention to the non-HOX class and the possible mechanisms through which they contribute to leukemic transformation.
INTRODUCTION
The finding of specific chromosomal rearrangements in acute leukemia first suggested that genes at these loci were responsible for transformation [1, 2] . Transcription factors are frequent targets in these lesions, and rearrangements can result in the generation of fusion proteins, as in E2A-PBX1 associated with pre-B-cell acute lymphoblastic leukemia (ALL) or the juxtaposition of tightly regulated genes next to highly active promoter regions. Immunoglobulin (Ig) and T-cell-receptor (TCR) loci are often involved in the latter scenario, most likely due to the fact that these genes normally undergo rearrangement during B-and T-cell development.
Evaluation of breakpoint regions within translocations in leukemia patients and retroviral insertion sites associated with hematologic malignancies in murine models has implicated several members of the homeodomain-containing (HD) family of transcription factors in leukemogenesis. HD transcription factors contain a 61-amino-acid helix-turnhelix DNA-binding domain [3] . Sequences flanking the HD also influence specificity by coordinating interaction with cofactor proteins that influence DNA-binding properties.
HD encoding (homeobox [HB] ) genes are broadly divided into two classes. Class I includes clustered HB (HOX) genes, recognized for their role in anteroposterior patterning during embryogenesis, while the class II divergent HB (non-HOX) genes are dispersed throughout the genome. The HOX gene loci are believed to have arisen from gene duplication and consist of 13 paralogous groups Stem Cells ® Concise Review organized into four clusters (A-D) on chromosomes 7, 17, 12, and 2, respectively. HOX genes exhibit high homology to the HOM genes of Drosophila, with groups 1-8 being most closely related to Drosophila antennapedia (Antp), and groups 9-13 more closely related to Drosophila abdominal-B (Abd-B) [3, 4] . During embryonic development, genes of paralogous groups 1-13 are sequentially expressed 3′ to 5′ along the anteroposterior axis and are regulated in a temporal and spatial manner.
HOX gene expression has been identified in normal hematopoietic tissues, including primary human CD34 + stem/progenitor cells, and in leukemic samples [5, 6] . Only expression of HOX genes from paralogous groups A, B, and C has been detected in normal hematopoietic cells, while expression from all clusters has been demonstrated in leukemic cells. The function of HOX genes in hematopoiesis has been investigated through knockout mouse models and enforced overexpression from retroviral vectors in hematopoietic stem cells from murine fetal liver and bone marrow and in human cord blood progenitors. Overexpression of HOXA10 in murine hematopoietic stem cells leads to perturbations in myeloid and B-cell differentiation, expansion of megakaryocyte progenitors, and ultimately, myeloid leukemia [7] . Mice lacking Hoxa9 have disrupted hematopoiesis, including lower numbers of lymphocytes, granulocytes, and committed progenitors of several cell lineages, but retain normal levels of more primitive progenitors with long-term culture-initiating cell activity. Conversely, overexpression of Hoxa9 results in defective Tcell development as well as acute myeloid leukemia (AML) [8] [9] [10] . HOXA5 overexpression in human bone marrow and cord blood progenitors leads to a selective greater number of myeloid cells and lower BFU-E numbers and erythroid differentiation, while the use of antisense oligonucleotides targeting HOXA5 results in a higher number of erythroid progenitors and fewer myelomonocytic cells [11, 12] . There is a strong correlation between HOXB6 expression and erythroid development, since targeted disruption of Hoxb6 results in an expansion of erythroid progenitors, and inhibition by antisense methodology decreases erythroid differentiation [13, 14] . However, HOXB6 expression also has been detected in myelomonocytic cell lines [15] . HOXB4 overexpression in embryoid bodies confers engraftment potential and induces a greater number of repopulating cells in murine bone marrow, without evidence of leukemic transformation [16] [17] [18] [19] . In contrast, ectopic expression of HOXB3 in murine bone marrow, which is normally expressed in the CD34 + 
Lin
-(lacking lineage differentiation markers) progenitor population, results in a disruption of lymphoid differentiation, greater granulopoiesis, and myeloproliferative disease (MPD) [20] . HOXC gene transcripts have been identified in a number of hematopoietic subpopulations but have not been directly implicated in leukemogenesis. However, a number of these genes are expressed in neoplastic cells of the lymphoid lineage [21, 22] . Expression of Hoxc6 has been detected in erythroleukemic cell lines and correlates with stage of differentiation of these cells, since the use of antisense oligonucleotides to Hoxc6 inhibits late-erythroid but not BFU-E-derived colony formation [23, 24] . Expression of HOXD genes has been demonstrated in a small number of leukemic cells, including HOXD3 in the HEL erythroleukemic cell line [25] and HOXD13, which is fused to NUP98 in AML [26, 27] . These and other studies imply that HOX proteins play a direct role in normal differentiation of hematopoietic cells, with some specificity in the lineages that they influence, and that leukemia may arise due to overexpression (or perhaps absence) of HD transcription factors.
Several non-HOX HD proteins have been shown to function as cofactors for HOX proteins and are cosynthesized during embryonic development. These include the three-amino-acid-loop-extension (TALE) proteins, PBX, MEIS, and PREP1/KNOX1. PBX genes are widely expressed in fetal and adult tissues, although PBX1 transcripts are notably absent from lymphocytes [28] . PBX proteins interact preferentially with the 3′ HOX proteins homologous to Antp and have been shown to influence cooperative DNA binding in vitro. PBX1 is the most frequently activated non-HOX HB oncogene in human leukemia, being translocated in 20% of pre-B-cell ALL cases to create a fusion protein with the transcription factor E2A [29, 30] . The MEIS family of cofactor proteins was initially recognized during studies of the myeloid leukemias that frequently develop in BXH-2 mice. Meis1 was found to be routinely coactivated with Hoxa7 and Hoxa9, suggesting that it acts in a cooperative capacity in leukemia development [31, 32] . MEIS proteins have been shown to preferentially interact with 5′ HOX proteins homologous to ABD-B as well as to PBX proteins [33] . PREP1/KNOX1, which encodes a protein that is normally associated with PBX proteins and plays a regulatory role in PBX availability, is broadly expressed; to date, it has not been associated with leukemic transformation [34] [35] [36] .
Other non-HOX HB genes are more restricted in their patterns of expression, and their encoded HD proteins are involved in organogenesis or differentiation of specific cell types. The HOX11 protein is required for spleen development and is not normally expressed in adult tissues. However, HOX11 is highly expressed in transformed T-cell precursors bearing the t(10;14) or t(7;10) translocation found in a subset of T-cell ALL (T-ALL), where it is translocated to TCR loci [37] [38] [39] [40] [41] . A number of other non-HOX HB genes are expressed in normal and malignant hematopoietic cells and are discussed below.
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HOX GENES IN LEUKEMOGENESIS
HOX gene involvement in leukemic transformation was initially inferred by the identification of constitutive activation of the Hoxb8 (Hox2.4) gene in the WEHI-3B myeloid leukemic cell line [42] . Transcriptional activation of Hoxb8 was attributed to insertion of an endogenous intracisternal A particle (IAP) provirus into a region upstream of the Hoxb8 gene, presumably leading to a block in differentiation of myeloid lineage cells [43] . In addition, coactivation of the interleukin-3 (IL-3) gene by an IAP element was assumed to have provided autocrine stimulation for the myeloid leukemic cells and contributed to the transformed phenotype [44, 45] . Experimental overexpression of the IL-3 gene alone in murine bone marrow cells results in overproduction of differentiated myeloid cells, while ectopic Hoxb8 expression results in the generation of IL-3-dependent myelomonocytic, megakaryocytic, and mast cell lines in vitro, and eventually, leukemia in vivo after a long latency period [44, 46] . Notably, enforced expression from retroviral vectors revealed that the combination of the two genes is potently transforming, with mice rapidly developing aggressive tumors [44] .
Further evidence for the involvement of HOX genes in leukemia came from the identification of retroviral coactivation of Hoxa7 and/or Hoxa9 with the Meis1 gene in BXH-2 mice [32, 47] . BXH-2 mice have naturally high spontaneous activation of endogenous murine leukemia virus with a corresponding greater incidence of myeloid leukemia. Cloning of the integration sites led to the identification of the insertionally activated Hoxa7 and Hoxa9 genes in the leukemic cells as well as the discovery of the prototypic member of the Meis family of non-HOX HB genes (Meis1) [31] . These studies, involving the BXH-2 mouse strain, have provided a model for the concept of non-HOX HD cofactors as accelerators of leukemic transformation, which has been subsequently confirmed by experimental coexpression of HOX and non-HOX HB genes in primary hematopoietic precursors. Enforced expression of Hoxa9 in murine bone marrow results in AML, and coexpression of Hoxa9 and Meis1b results in accelerated development of leukemia in mice compared with expression of Hoxa9 alone [9] . Coexpression of HOXA9/HOXA7 and MEIS1 has been observed in human AML, suggesting that collaboration between HOXA9 and MEIS1 is relevant to human leukemogenesis [48, 49] .
In a small subset of human AML, the HOXA9 gene is fused to the NUP98 gene, which encodes a component of the nuclear pore complex, as a result of the t(7;11)(p15;p15) chromosomal translocation [50, 51] . The chimeric protein retains the HD of HOXA9 and the phenylalanine-glycine (FG) repeats from NUP98 [51] . Enforced expression of NUP98-HOXA9 in NIH3T3 cells results in transformation, assessed by colony growth in soft agar, and MPD followed by AML in mice transplanted with transduced bone marrow cells [52, 53] . The oncogenic potential of NUP98-HOXA9 has been attributed, at least in part, to the FG repeats, which are capable of interacting with the transcriptional coactivator, cAmp-response-element-binding (CREB)-binding protein (CBP/p300) [52] . NUP98 also forms a fusion protein with HOXD13 and the non-HOX HD protein PMX1, demonstrating that NUP98 is a frequent target of chromosomal translocations [26, 27, 54] . In all cases, the NUP98 FG repeats are preserved. HOXA9 can also be a potent repressor of transcription, a property that is associated with its N-terminal domain, but which is lost upon fusion with NUP98 [52] . Loss of repressor activity may contribute to its oncogenic potential.
The HOXA9 HD and association with PBX via a tryptophan-containing PBX-interaction motif (PIM) are required for NUP98-HOXA9-mediated transformation of NIH3T3 cells. Since in vivo transformation due to coexpression of Hoxa9/Meis1 involves overexpression of full-length proteins, transformation due to NUP98-HOXA9 may occur through different mechanisms, specifically by cooperation with PBX proteins. A potential difference in mechanisms is further suggested by the observation that NUP98-HOXA9 induced MPD in advance of AML, a condition not seen when Hoxa9 was expressed alone or when Hoxa9 was coexpressed with Meis1 [53] . However, NUP98-HOXA9 was shown to cooperate with Meis1 in murine bone marrow transduction experiments to accelerate development of AML, although to a lesser extent than seen with Hoxa9/Meis1. Moreover, coexpression of NUP98-HOXA9/Meis1 was not acutely transforming [53] . The nature of the interaction between NUP98-HOXA9 and Meis1 is not clear, since the portion of HOXA9 responsible for interaction with Meis1 is deleted in the fusion protein. Therefore, parallel oncogenic pathways may be activated, a model that is supported by the observation that ectopic coexpression of Meis1 with HOXB3 in murine bone marrow precursors accelerated induction of AML-like disease [55] .
Interestingly, while Hoxa9 does not cooperate with Pbx1 to influence the onset of leukemogenesis, it does appear to work synergistically with E2A-PBX1 and results in rapid development of AML in which primitive hematopoietic cells are the primary target [56] . Although they have not been directly implicated in human leukemia, murine bone marrow transduction experiments with retroviral vectors have demonstrated that ectopic expression of a number of other HOX genes can perturb hematopoiesis. As noted above, mice transplanted with bone marrow expressing high levels of HOXA10 ultimately developed AML after a long latency [7] . By comparison, Hoxb4 overexpression selectively induced Owens, Hawley 366 the expansion of hematopoietic stem cells but did not result in leukemic transformation [16, 18] , whereas constitutive expression of Hoxb3 resulted in perturbation of lymphocyte development and MPD [20, 57] .
Since experimental data suggest that HOX genes have the potential to contribute to leukemia more than initially appreciated, inappropriate activation through demethylation or disruption of transcriptional regulatory pathways may also activate HOX gene expression in leukemic cells. In Drosophila, the trithorax (Trx) gene is required for maintenance of HOM gene expression, while polycomb (PcG) genes negatively affect HOM gene expression [58, 59] . This is of particular relevance, since the human ortholog of Trx, MLL, which is located at chromosome 11q23, is frequently involved in translocations associated with biphenotypic or mixed-lineage leukemia [60] . MLL is required for normal hematopoiesis since Mll +/-mice are anemic and have lower B-cell populations and myeloid lineage cell numbers [61] . Furthermore, analysis of yolk sac cells revealed that early hematopoiesis was affected in heterozygous and homozygous null mutants [62] . Body patterning and Hox gene expression are altered in Mll +/-mice, as in Trx +/-Drosophila, and the changes are consistent with the hypothesis that Mll is involved in maintenance rather than initiation of Hox gene expression [63] . Interestingly, a correlation has been made between a specific translocation involving MLL, t(4;11), and the upregulation of HOXA9 and MEIS1 expression in ALL [64] . This observation provides support for the notion that aberrant HOXA9 and MEIS1 coexpression in some cases of human leukemia may be due to indirect mechanisms.
TALE COFACTOR PROTEINS
Many HD proteins bind to common or similar DNA targets in vitro. In order to increase the specificity of the target sequence, HOX proteins interact with non-HOX HD cofactor proteins, and it is believed that these complexes can activate or repress a specific array of genes ( Fig. 1) . Members of the TALE family of non-HOX HD cofactor proteins, which include PBX, MEIS, and PREP1/KNOX1 proteins, are distinguished from other HD proteins by the inclusion of an additional three amino acids between α-helices 1 and 2 within the HD. Evidence from mouse models and human leukemic cells has indicated that inappropriate expression of TALE cofactors with certain HD proteins may contribute to leukemic transformation, while overexpression of TALE cofactors alone does not lead to disease development. However, as noted above and discussed in detail below, one of these proteins, PBX1, has oncogenic potential in the form of a fusion protein with E2A.
The PBX1 gene was originally identified at the breakpoint of the t(1;19) translocation found in childhood pre-B-cell ALL [29, 30] . Subsequently, two other PBX genes were identified [28] . The Drosophila ortholog of PBX, extradenticle (exd), has been shown to interact with Drosophila HOM genes and influence segment identity [65] [66] [67] [68] . PBX genes are widely expressed among different cell types, including hematopoietic cells, although PBX1 is somewhat restricted in its expression compared with PBX2 and PBX3. Knockout studies of Pbx1 revealed its critical role in myelopoiesis; a severe reduction in common myeloid progenitors was observed in Pbx1-deficient animals, which died in utero due to anemia [69] .
PBX proteins have been demonstrated to interact with HOX proteins in vitro on DNA target sequences, each protein binding to a specific DNA half site [70, 71] . PBX modulates the DNA binding of HOX proteins, and this interaction is mediated through the PIM located N-terminal to the HD in HOX proteins and through sequences in the HD and the C-terminal portion of PBX [72] [73] [74] . PBX proteins do not directly interact with 5′ HOX proteins since the pentapeptide motif is absent in paralogous groups 11-13. Instead, HOX proteins of groups 11-13 interact with MEIS/PREP proteins via N-terminal sequences in HOX, while paralogous groups 9 and 10 can interact with both PBX and MEIS/PREP [75] . Given that HOX proteins of paralogous groups 9 and 10 can interact with both PBX and MEIS, target gene expression may be dependent on differential availability of these cofactors.
While MEIS1 was discovered in the context of leukemia, a related factor, PREP1 (PBX-regulating protein), was identified as a constituent of urokinase enhancer factor 3 (UEF3), associated with the induction of urokinase plasminogen activator expression [34] . PREP1 bears high homology to MEIS1 in two N-terminal regions, HR1 and HR2, and interactions between MEIS/PREP1 and PBX are mediated by N-terminal sequences from both proteins. However, in contrast to MEIS1, PREP1 was incapable of accelerating leukemogenesis when coexpressed with HOXA9 [55] .
MEIS/PREP1 proteins regulate PBX availability for HOX proteins by inducing a conformational change in PBX that uncovers nuclear localization signals in the PBX HD [76] [77] [78] ; PBX mutants with a deletion in the N-terminal domain of PBX accumulate in the nucleus since the nuclear localization sequences are no longer masked [78] . Furthermore, nuclear import of Drosophila Exd has been observed downstream of Wingless and Decapentaplegic signaling [79] , suggesting that extracellular signaling can modulate the availability of PBX for HOX protein function through interaction with MEIS/PREP1 in mammalian systems.
Higher order complexes of HOX/PBX/MEIS proteins have been isolated from several cells types and, depending on the target sequence, some or all of the HDs may physically interact with the DNA [80] [81] [82] . Trimer complexes of 367 HOXA9/PBX/MEIS have been isolated from myeloid cells in the absence of DNA binding [82] . This observation is somewhat at odds with the demonstration that Hoxa9 can immortalize bone marrow progenitors in the absence of Meis1 [83] , but may indicate that multiple pathways are concurrently activated.
The contribution of intact TALE HD proteins to transformation seems to be primarily related to their function as cofactors leading to augmentation of the transcriptional signal. However, the E2A-PBX1 fusion protein is oncogenic in humans and in murine models. E2A-PBX1 arises as a result of the fusion of two N-terminal transactivation domains from the basic helix-loop-helix transcription factor E2A with the majority of the PBX1 protein, including the HD. The E2A gene encodes two proteins, E12 and E47, required for initiation of B-cell lymphopoiesis, and thus, expression of the E2A-PBX1 fusion protein is directed to the pre-B-cell compartment [84] . In addition to its oncogenic role in B-cell neoplasia in humans, E2A-PBX1 has been shown to transform fibroblasts that give rise to tumors in nude mice and to induce myeloid malignancies preceded by MPD in mice transplanted with E2A-PBX1-transduced bone marrow [56, 85] . Ectopic E2A-PBX1 expression in murine hematopoietic precursors in vitro resulted in the generation of factor-dependent myeloid progenitor cell lines, suggesting that E2A-PBX1 is primarily involved in blocking differentiation [86] . E2A-PBX1 transgenic animals have also been shown to develop premalignant disease involving the spleen and thymus [87] . Cells carrying the E2A-PBX1 transgene exhibit greater rates of cell death as well as proliferation, and the animals ultimately develop T-cell lymphomas. Mutational analysis has demonstrated that the transactivation domains of E2A are essential for transformation. Structure-function studies indicate that the HD is dispensable for transformation of fibroblasts in vitro or T lymphocytes in vivo, but the HOX cooperativity motif and other portions of PBX N-terminal to the HD are required [68, [88] [89] [90] . In contrast, the HD is essential for immortalization of myeloid cells [89] . PBX1 repressor function has been localized to an N-terminal domain, which is retained in E2A-PBX1 and appears to be independent of specific DNA binding. This domain may mediate repression through as yet unidentified cellular factors and may account for the difference in transforming capabilities of E2A-PBX1 mutants in NIH3T3 cells and T lymphocytes relative to myeloid cells.
Several possible mechanisms of transformation have been proposed. Addition of the activation domains from E2A confers dominant transactivating activity on PBX1 and, likely, leads to inappropriate downstream gene expression. Indeed, E2A-PBX1 is a strong activator of transcription from the PBX responsive sequence (PRS), whereas PBX alone can bind at this site but is incapable of initiating transcription [91] [92] [93] . Overexpression of E2A-PBX1 may compete for DNA target sites, resulting in displacement of PBX2 and PBX3, both of which are normally expressed in B cells. Constitutive activation at responsive sites, which would otherwise be tightly controlled, would lead to a loss of gene regulation. Transformation may, therefore, occur due to overexpression of the E2A-PBX1 fusion protein, which then cooperates with 3′ HOX proteins, amplifying their effects inappropriately in the pre-B-cell compartment. Evidence for such cooperation, albeit in myeloid cells, was provided by experimental data showing that combining E2A-PBX1 with HOXA9 resulted in acceleration of AML [56] . In addition, since PBX1 interacts with MEIS/PREP1 proteins via its N-terminal domain, including the region that is deleted in the chimeric E2A-PBX1 oncoprotein [94] , E2A-PBX1 may be restricted from binding to PBX/MEIS target sites. Altered subcellular localization may also be a factor, since E2A-PBX1 is confined to the nucleus.
As discussed above, HD cofactors can contribute to leukemia development in the case of HOXA7/9 and MEIS1 [48, 49] . HOXB3 and HOXB4 also have been shown to interact with PBX1, and coexpression of these genes resulted in greater colony formation in soft agar, as well as higher rates of proliferation and transformation of Rat-1 cells [95] . Hoxb8 requires interaction with Pbx1 to arrest myeloid differentiation [96] .
ANTP SUPERCLASS OF DIVERGENT HB GENES
There are numerous other HD proteins, beside those cofactors for HOX proteins, that have specific functions in organogenesis and tissue differentiation. Several of the corresponding HB genes occur in clusters dispersed throughout the human genome that are conserved in other organisms. Phylogenetic analysis of the ANTP superclass of genes suggests that these dispersed HB genes also arose due to gene duplication, since a number of common clusters have been identified in amphioxus (Branchiostoma belcheri), Drosophila, mice, and humans. These clustersextended HOX, NKL, paraHOX, and EHGbox-are believed to have diverged early during vertebrate evolution [97] . For example, the 93D/E cluster in Drosophila, related to the NK cluster in mammalian genomes, contains several genes, including 93Bal and ladybird late, that are homologous to the HOX11 and LBX genes, respectively, which map to 10q24 in the human genome [98, 99] . A few of these tissue-and organ-specific HB genes have been implicated in leukemogenesis and are discussed here.
HOX11/TCL3 and HOX11L2
The diverged HB oncogene, Hox11, has been proposed to act as a survival factor for splenic precursors and is required for organogenesis of the spleen, since Hox11 -/-mice are asplenic [100, 101] . HOX11 (TCL3) was originally identified at the breakpoint of the t(10;14) translocation found in 7%-10% of pediatric T-ALL cases, and subsequently, in the t(7;10) translocation [37, 38, 40] . Rearrangements involving HOX11 juxtapose the intact gene next to TCRδ or TCRβ regulatory regions. As a result, the fulllength protein is expressed at high levels in thymocytes, in which it is otherwise absent, suggesting that its deregulation is an early step in leukemogenesis [102] . In addition to participating in two known translocation events in T-ALL, HOX11 is also frequently activated in T-ALL in the absence of overt genetic rearrangement. Promoter demethylation was correlated with HOX11 activation in the T-ALL specimens examined, regardless of whether it was found to be translocated [103] . These data showed that HOX11 was expressed in up to one-third of T-ALL cases. HOX11 can behave as an oncogene in other contexts under experimental conditions. Constitutive expression of HOX11 from the murine stem cell virus retroviral vector in murine bone marrow results in immortalization of hematopoietic precursors and subsequent leukemia formation with long latency (7-12 369 months) [39, 104] . Enforced expression from IgHµ transcriptional regulatory sequences in transgenic animals induced mature B-cell lymphomas over a 20-month period [105] . These results suggest that HOX11 is specifically associated with T-cell malignancy in humans because of aberrant TCR rearrangement. In other studies, ectopic HOX11 expression during in vitro hematopoietic differentiation of murine embryonic stem cells efficiently led to the establishment of novel cell lines with primitive and definitive erythroid properties [106] . Collectively, these findings suggest that the transforming capacity of HOX11 derives from its ability to alter gene expression programs regulating hematopoietic differentiation pathways.
HOX11 contains a partial Hep motif (named for its presence in H2.0, engrailed and paired HD proteins), which may be involved in transcriptional repression activity, and a pentapeptide motif (FPWME) for PBX interactions. Recent data suggest that TALE HD cofactor interactions may be important for transformation induced by HOX11 [107] . HOX11 can interact with all PBX proteins, and PBX2 is highly expressed in the ALL-SIL and K3P T-ALL cell lines, which contain the t(10;14) translocation. In addition, trimeric complexes of HOX11, PBX2, and MEIS1b were shown to exist in vitro, and coexpression of HOX11 and PBX2 from a retroviral vector induced focus formation in NIH3T3 cells [107] .
HOX11-mediated transformation may be a result of de novo expression of downstream HOX11 target genes or competition with the DNA-binding sites of HOX genes, blocking or mimicking their effects. Several studies have suggested a number of possible models. HOX11 interacts with CCAAT-box-binding transcription factor 1 (CTF1) in a HOX11-immortalized hematopoietic progenitor cell line [108] . CTF1 is a ubiquitous transcription factor that interacts with TFIIB, a component of the basal transcriptional machinery, suggesting a mechanism by which HOX11 directly regulates transcriptional activation or repression. Representational difference analysis for investigation of HOX11 target genes in transduced NIH3T3 cells identified the aldehyde dehydrogenase 1 (Aldh1) gene [109] . The possible significance of ALDH1 in leukemogenesis is uncertain though, since it does not appear to be expressed in HOX11-positive T-ALL cells [109] . Another potential downstream target of HOX11 is the Wilms' tumor (WT) 1 tumor suppressor gene, a zinc finger-containing transcription factor, homozygous deletion of which is associated with pediatric nephroblastoma. Wt1 is required for spleen development [110] and appears to act downstream of Hox11 during spleen organogenesis [111] , but whether expression of WT1 is regulated by HOX11 in T-ALL is not known. Our data show that HOX11 can act as a repressor of transcription, possibly by interfering with a component of the basal transcriptional machinery, and repression occurs in the absence of PBX cofactor interactions or an obvious HD DNA-binding site (our unpublished observations). The consequences of HOX11 expression may, therefore, be dependent on cellular context and cofactor availability. HOX11 has also been shown to interact with the serine/threonine protein phosphatases, PP1 and PP2A, and to disrupt a G 2 /M cell-cycle checkpoint [112] . Interaction with PP1/PP2A occurs in the absence of DNA binding and indicates a possible DNAindependent mechanism of HOX11-transforming function.
Recently, the HOX11 family member, HOX11L2, was found to be transcriptionally activated as a result of the t(5;14)(q35;q32) translocation in T-ALL [113] . Notably, HOX11L2 overexpression was also identified in a subset of HOX11-negative T-ALL samples that exhibited the gene expression signature associated with authentic HOX11-expressing cases revealed by gene profiling experiments [114] . Highlighted in this study was a correlation between HOX11L2 expression and a less favorable disease outcome compared with HOX11-positive leukemia. While the basis for this remains to be determined, these new findings suggest that the HOX11 family of HB genes contributes to T-ALL more than previously appreciated.
HLX/HB24
Human and mouse orthologs of HLX (HB24) were independently identified from an activated human B-cell library and a murine pre-B-cell library, respectively [115, 116] . The HLX protein contains a Hep motif but lacks a PBX interaction motif. HLX is normally expressed in a number of tissues, including the mesenchyme of developing animals, primarily in regions that give rise to the liver, gall bladder, and gut [117] . HLX is also expressed in hematopoietic cells, including bone marrow cells enriched for CD34
+ precursors [115, 116, 118] . Hlx knockout animals died at E15 due to anemia and lack of development of liver and gut [119] . Failure in hematopoiesis was shown to be due to impaired liver development, since fetal liver cells from Hlx -/-mice were transplantable and could reconstitute irradiated animals. It has been proposed that Hlx is involved in regulating epithelial-mesenchymal interactions in these tissues as well as in the placenta [120] .
Although not essential for hematopoiesis, transgenic mice with HLX placed under the control of the TCRβ promoter exhibit altered T-cell development [121] . Specifically, ectopic HLX expression inhibited the differentiation of double-positive thymocytes into CD4 + T cells. Similarly, transgenic mice expressing murine Hlx in the B-and T-cell compartments exhibited defects in both B-and T-cell development [122] . In addition to its potential to disrupt Owens, Hawley 370 normal T-cell development, HLX enhanced tumorigenicity of the Jurkat T-cell line in nude mice [123] . HLX-expressing Jurkat T cells exhibited a greater rate of cell-cycle progression and upregulation of cell-surface activation markers (human leukocyte antigen DR, IL-2Rα, leukocyte function-associated antigen-1) [124] . As elevated levels of HLX have been observed in acute leukemias, it is possible that this HB gene may contribute to the leukemic phenotype in some instances [125, 126] .
HEX
HEX (hematopoietically expressed HB; Hhex/Prh) was initially identified in human hematopoietic cells, where it is expressed in multipotential progenitors, myeloid cells, and B cells, but not T or erythroid cells [127] . HEX expression has also been detected in peripheral blood leukocytes from leukemia patients [127, 128] . HEX/Hex expression is downregulated upon progenitor cell differentiation to monocytes/macrophages and megakaryocytes, while maintained or upregulated in granulocytes. Outside of the hematopoietic system, HEX/Hex transcripts have been detected in adult liver, lung, and thyroid tissues [129] [130] [131] [132] [133] . During embryogenesis, Hex is expressed in the forebrain, fetal liver, and thyroid [131] and is an early marker of endothelial cell precursors [133] .
HEX is highly conserved across species, and orthologs have been identified in chicken, where it is expressed in bone marrow, peripheral blood and bursa, lung, and liver cells [134] , as well as zebrafish and Xenopus. The HEX gene is located on chromosome 10 at 10q23 near HOX11 with which it shares high sequence similarity [127, 130] . Interestingly, HEX lacks the PIM but does contain a Hep motif within its N-terminus. HEX can repress transcription in vitro and in vivo, and in the zebrafish, overexpression of Hex results in the downregulation of bmp2b and wnt8 [132, 135, 136] . Interestingly, the HD is not required for repression in vitro, suggesting that sequestration of transcription factors may be a possible mechanism of repression. Hex -/-mice died at day E10.5 due to lack of liver formation [137] . Examination of hematopoiesis revealed normal differentiation of erythroid colonies, but granulocyte-macrophage colony-forming cell differentiation was impaired and monocytes were fewer or absent [137] .
The possibility that HEX may be involved in leukemic processes is suggested from its expression in a number of human leukemia samples and from experimental evidence of retroviral insertional activation in B-cell leukemias arising in AKXD mice [138] . Interestingly, an interaction between Hex and c-Jun, a component of the AP-1 transcription factor complex, has been identified in which Hex binds to the N-terminal portion of Jun via the third helix of its HD [139] . Hex preferentially binds to Jun/Fos dimers, repressing transcription from AP-1 target sequences. Since AP-1 complexes mediate the transcriptional response to extracellular signals from growth factors, disruption of these pathways could have significant effects on cell differentiation or apoptosis.
PMX1
PMX1 (Mhox1/Prx1/Phox1) is a member of the paired HB family of genes, but it also bears considerable homology with members of the ANTP HB gene family. It is primarily associated with embryonic mesoderm development and is involved in skeletal, heart, and forebrain development [140] . Knockout mice have abnormal vasculature and surrounding matrix as well as impaired skeletogenesis [141] . PMX1 does not appear to have a primary role in hematopoiesis, but it was identified as part of a fusion protein involved in the t(1;11)(q23;p15) translocation, which places the activation domain of NUP98 upstream of PMX1, resulting in constitutive expression. PMX1 can also interact with Maf oncoproteins to inhibit their DNA binding and transforming potential [142] . The relationship is not well understood, but inappropriate interaction with Maf proteins could potentially disrupt myeloid or erythroid differentiation schemes regulated by c-Maf or MafB, respectively. A further potential mechanism of action for PMX1 is implied by the observation that it and other members of the paired HB family can interact with pRB proteins, a family of tumor suppressor proteins that are frequently targeted in transformation [143] .
DLX
The DLX genes are related to the Drosophila distal-less gene. To date, eight DLX-like genes have been identified in humans. DLX7, which maps to chromosome 17q23, is expressed in normal bone marrow cells and leukemic cell lines with erythroid characteristics, e.g., K562 and HEL [144] . DLX7 levels increase upon differentiation of HEL with hemin, and antisense oligonucleotides to DLX7 in K562 lead to apoptosis and decreases in c-MYC and GATA1 levels. Therefore, DLX7 may be involved in hematopoietic cell survival and/or proliferation. A related gene, BP1, is also overexpressed in a large number of acute leukemias, particularly those of the monocytic lineage [145] . BP1 was originally identified as a repressor of β-globin gene expression; K562 cells overexpressing BP1 had a greater ability to grow in soft agar, suggestive of greater oncogenic potential [145] . Sequencing analysis suggests that DLX4, DLX7, and BP1 may be splice variants of a common gene, since they exhibit high levels of sequence identity [146] . Downstream target genes may be differentially regulated by this set of proteins, 371 since DLX7 binds to silencer I DNA located upstream of the β-globin gene but does not repress transcription [147] .
LHX2
LIM domains are zinc-finger-like domains that are associated with protein-protein interactions rather than direct DNA binding. LHX2 (LH2; LIM-HD protein 2) was independently cloned from a pre-B-cell library and as an activator of the glycoprotein hormone α subunit, and is expressed in the γδ subset of T cells and the developing nervous system [148, 149] . Knockout mouse models demonstrated the requirement for Lhx2 for efficient development of definitive erythropoiesis [150] . The defect in erythroid development is likely to be due to a compromised fetal liver microenvironment rather than an intrinsic hematopoietic cell defect, since transplant of fetal liver cells into lethally irradiated mice resulted in reconstitution of erythropoiesis [150] .
LHX2 expression has also been found at high levels in chronic myelogenous leukemia (CML) patients [151] . The LHX2 gene is located proximal to the region of chromosome 9 involved in the Philadelphia translocation and has been proposed to be activated, in part, due to the expression of BCR-ABL [152] . The significance of LHX2 expression in CML cells is unclear though, since LHX2 mRNA is also found in leukocytes from normal individuals, patients with chronic myeloproliferative disorders, and in Epstein-Barr virus-derived lymphoblastoid cell lines from CML patients, regardless of the status of BCR-ABL [153] . However, Lhx2 can immortalize kit ligand-dependent hematopoietic cell lines derived from murine embryonic stem cells differentiated in vitro [154] . These cell lines have the surface phenotype of hematopoietic stem/progenitor cells (CD34 + , c-kit + ). Moreover, Lhx2 can also immortalize hematopoietic stem cells in murine bone marrow with long-term engrafting potential as measured by serial transplantation in W 41 /W 41 (ckit-defective) recipients [155] , arguing for a role of LHX2 in CML pathophysiology.
GBX2
Gastrulation and brain specific-2 HB gene (GBX2) is highly conserved among humans, mice, and chickens [156] . It has been particularly associated with prostate cancer and may be a marker of metastatic disease [157] . GBX2 has also been identified as a downstream target of the Myb oncogene; therefore, while it has not been directly implicated in human leukemia, it appears to be an intermediate of signaling through a pathway involved in myeloid cell differentiation [116, 141, 153, 158] . In the avian system, the v-myb oncogene associated with avian myeloblastosis virus induces the expression of Gbx2, which leads to the production of chicken myelomonocytic growth factor, allowing autocrine growth stimulation of myeloid leukemic cells. Since Gbx2 induces an autocrine phenotype in cells that are dependent on exogenous cytokines for growth, a possible mechanism is suggested through which this HD protein could provide an early step during leukemic progression.
CDX2
The normal expression of CDX2, a caudal-related HB gene, is tightly restricted to intestinal development. Lower expression of CDX2 has been associated with colorectal carcinoma, and mice heterozygous for Cdx2 have a propensity for developing adenomatous polyps and colon tumors [159] [160] [161] [162] . CDX2 expression could be restored in a colorectal cancer cell line by introduction of a functional copy of the APC tumor suppressor gene, suggesting a critical relationship between these factors in colorectal carcinogenesis [160] . CDX2 is not normally expressed during hematopoietic differentiation, but it has been identified as one of the components in a fusion protein found in AML. This is, thus, another example (e.g., HOX11, PMX1) where a developmentally regulated HD protein not normally associated with hematopoiesis has been commandeered for leukemic outcome. CDX2 was identified as one of the genes involved in the t(12;13) translocation, fusing ETV6 (TEL) and CDX2 [163] . CDX2 expression was also observed in a case of leukemia lacking the translocation, indicating that CDX2 expression may be dysregulated through other means. CDX2 has been shown to interact with CBP in the Caco-2 intestinal cell line and to potentiate its transcriptional activity, suggesting that aberrant expression of downstream targets could represent a possible mechanism of CDX2-associated transformation in both colorectal carcinoma and leukemia [164] .
MOLECULAR MODELS OF HB-GENE-MEDIATED TRANSFORMATION
A number of models involving transcriptional activation or repression have been proposed to account for how HB genes may contribute to leukemogenesis (Fig. 1) . HOX genes are preferentially expressed in primitive hematopoietic cells [5] . Therefore, inappropriate expression of HB genes or generation of a constitutively active HD-containing fusion protein could result in persistence of downstream target gene expression, perpetuating signals that prevent differentiation, and/or result in greater proliferation of hematopoietic precursor cells.
Overexpression of non-HOX HD cofactor proteins, such as PBX or MEIS, or loss of regulation by MLL, can alter HOX protein function and levels. Experimentally, non-HOX HB gene cofactor activation, when coupled with HOX gene overexpression, has been shown to lead to a Owens, Hawley 372 rapidly developing acute leukemia [9, 32, 44, 47] . The probability of formation of HOX-containing complexes capable of DNA binding and transcriptional activation or repression increases in the presence of excess PBX or MEIS, since neither the cofactors nor the HOX proteins are limiting. Interestingly, although overexpression of HOXA10 in murine hematopoietic stem cells gives rise to myeloid leukemia [7] , ectopic expression of HOXA10 has been shown to upregulate the cyclin-dependent kinase, p21, and induce differentiation of U937 myelomonocytic cells [165] . Differential HD cofactor availability may account for these contrasting outcomes. The HOXA5 gene has been shown to transactivate the p53 gene promoter and is preferentially methylated in breast cancer cells [166] , concomitant with loss of expression of both genes. Although the p21 gene is a downstream effector of p53, no specific association between loss of HOXA5 expression (or loss of expression of other HOX genes) and leukemic hematopoiesis has been reported. Replacement of regulatory domains of HD proteins can also change the nature of the transcription factor. E2A-PBX1 is constitutively nuclear and acts as a transcriptional activator in contrast to wild-type PBX1, which has transcriptional repressor activity and requires association with MEIS/PREP1 for nuclear import. Similarly, a repressor domain of HOXA9 is deleted during the formation of the NUP98-HOXA9 oncoprotein [52] .
Experimental data have indicated that certain HD proteins can interact with transcriptional coactivators or corepressors depending on availability, potentially providing an explanation for the differences in gene expression observed in different cellular milieu. One class of coactivators is exemplified by CBP and p300. Interaction of NUP98-HOXA9 with CBP has already been discussed, and is hypothesized to be the means through which the fusion protein initiates aberrant gene expression. CBP and p300 are large, complex multidomain proteins that have inherent histone acetyltransferase activity and can participate in chromatin remodeling as well as acetylation of transcription factors [167, 168] . It is noteworthy that CBP/p300 can mediate both activation and repression of gene expression, and the proteins act as pro-or antidifferentiation factors depending on promoter context and associated factors. CBP/p300 interact with phosphorylated forms of CREB and other transcription factors, such as c-Jun, c-Fos, and p53, and can function as molecular scaffolds, bridging activators or repressors of transcription with the basal transcriptional machinery. Both are required for normal development, as the knockouts result in embryonic lethality. CBP is hypothesized to be a tumor suppressor gene, since it is targeted by various viral oncogenes including adenovirus E1A and simian virus 40 large T antigen, and heterozygosity in Rubenstein-Taybi syndrome (RTS) is characterized by a higher risk of malignancy in addition to multiple developmental abnormalities. CBP +/-mouse models of RTS exhibit extensive defects in normal hematopoietic differentiation with compensatory extramedullary hematopoiesis resulting in splenomegaly. Both humans and murine models exhibit a higher risk for hematologic malignancy. Interestingly, p300 +/-mice do not have the same phenotype, suggesting a special role of CBP in hematopoietic regulatory mechanisms.
Several HD proteins have been shown to interact directly with CBP. HOXB7 transactivation in transformed cells is induced by direct interaction with CBP, and this activity is augmented by the addition of trichostatin A, a histone deacetylase inhibitor [169] . The pancreatic factor, Pdx-1, can act as both a transactivator and a repressor. Analysis of the heterodimeric Pdx-Pbx fusion protein showed that transactivation was mediated through association with CBP via the Pdx-1 N-terminal domain. Conversely, repression was brought about by association with a specific protein isoform of Pbx1, since interaction with Pbx1a but not Pbx1b recruited N-CoR/SMRT corepressors [170] . Interestingly, E2A-PBX1b possesses greater transforming potential than E2A-PBX1a [171] , possibly reflecting differential interaction with corepressors. A similar observation was made with regard to the interaction of Hoxb1 on its autoregulatory element, in which HOX-PBX complexes recruit either corepressors (HDACs/N-CoR/SMRT) or CBP, a switch that was stimulated by extracellular signaling [172] . Hoxb1 does not efficiently activate or repress transcription in the absence of PBX, demonstrating that physical interaction with the HD cofactor protein is required.
Shen and colleagues further demonstrated that a direct interaction between HOX proteins and CBP could result in a block of CBP histone acetyltransferase activity [173] . The region of the HD protein that interacted with CBP varied, but for some HOX proteins, it was localized to the HD. However, broad association with CBP does not account for the specificity of functions mediated by HD proteins. Other mechanisms of HD protein-mediated repression have been described, including direct repression by interfering with other components of the basal transcriptional machinery, competition with coactivators for DNA-binding sites, and quenching of transcriptional coactivators by blocking their transactivating ability [174] [175] [176] [177] [178] [179] .
CONCLUSIONS
Studies of HB gene expression in primary human hematopoietic cells and leukemic samples, as well as knockout and retroviral transduction models, have provided evidence for the critical role of members belonging to both the HOX and non-HOX classes in hematopoietic regulatory 373 mechanisms and leukemic transformation. At present, only a limited number of HB genes are directly implicated in leukemogenesis in humans, but those identified contribute to a considerable proportion of the clinical cases. Moreover, given the high incidence of rearrangements involving MLL [60] and the recent appreciation of greater involvement of HOX11 family members in T-ALL [103, 113, 114] , it is conceivable that HOX and non-HOX HB genes may be more widely involved in hematologic malignancies than heretofore appreciated. The DNA sequences targeted by HOX protein/non-HOX HD cofactor complexes in vivo are still incompletely defined, and future studies better characterizing these will assist in distinguishing the key downstream target genes. Elucidation of the principal target genes regulated by HOX proteins during normal hematopoietic development will shed light on the manner in which the transcriptional networks they control are perturbed by aberrant expression of HOX and non-HOX HB genes, resulting in leukemia. 
ACKNOWLEDGMENTS
